Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Peloton Therapeutics

Peloton Therapeutics
2011 FOUNDED
PRIVATE STATUS
41-50 EMPLOYEES
Series E LATEST DEAL TYPE
$150M LATEST DEAL AMOUNT
17 INVESTORS
Description

Developer of early-stage cancer drugs intended to target unexploited molecular vulnerabilities. The company's drugs drive disease which have eluded conventional small molecule approaches, enabling patients with cancer and other serious or life-threatening conditions to avail oral drugs without any side effects.

Formerly Known As
Damascus Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2330 Inwood Road
  • Suite 226
  • Dallas, TX 75235
  • United States

+1 (972) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Peloton Therapeutics’s full profile, request a free trial.

Peloton Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series E) 20-Feb-2019 $150M 00000 00000 Completed Generating Revenue
6. Later Stage VC (Series D) 14-Mar-2017 000.00 00000 00000 Completed Clinical Trials - Phase 2
5. Grant 05-Aug-2016 0000 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 05-Nov-2014 000.00 000.00 000.00 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 18-Dec-2013 000.00 000.00 000.00 Completed Startup
2. Grant $11M $18M Completed Startup
1. Early Stage VC (Series A) 27-Jul-2011 $18M $18M 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Peloton Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series E 00,000,000 00.000000 00.0 00.00 00.00 00 00.00 000
Series D 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 10,080,000 $0.000100 $0.1 $1.25 $1.25 1x $1.25 7.68%
Series A 17,100,000 $0.000100 $0.08 $1 $1 1x $1 13.03%
To view this company’s complete Cap Table, request access »

Peloton Therapeutics Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BVF Partners Hedge Fund Minority 000 0000 000000 0
Curative Ventures Venture Capital Minority 000 0000 000000 0
Driehaus Capital Management Corporation Minority 000 0000 000000 0
EcoR1 Capital Hedge Fund Minority 000 0000 000000 0
Eventide Asset Management Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Peloton Therapeutics Executive Team (15)

Name Title Board
Seat
Contact
Info
John Josey Ph.D Chief Executive Officer & Board Member
Alan Musso Chief Financial Officer
Eli Wallace Ph.D Chief Scientific Officer
Zhaodan Cao Ph.D Director, Biology
Peter Stengel Ph.D Director, Chemical Development

1 Former Executive

You’re viewing 5 of 15 executives. Get the full list »

Peloton Therapeutics Board Members (13)

Name Representing Role Since Contact
Info
Brett Ringle JD Remeditex Ventures Board Member 000 0000
David Chang Ph.D Self Board Member 000 0000
David Goeddel Ph.D The Column Group Chairman 000 0000
Helen Kim The Column Group Board Member 000 0000
James Tananbaum MD Foresite Capital Management Board Member & Advisor 000 0000

1 Former Board Member

You’re viewing 5 of 13 board members. Get the full list »